About the Company
Moderna, Inc. ( mə-DUR-nə) is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. It also includes candidates that use OX40 ligand, interleukin 23, IL36G, and interleukin 12 for cancer immunotherapy, specifically treatment of breast cancer, urothelial carcinoma, lymphoma, and melanoma. Also being developed by Moderna is a regenerative medicine treatment that encodes vascular endothelial growth factor A to stimulate blood vessel growth for patients with myocardial ischemia.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRNA News
Moderna's CEO Says Staff Should Consult ChatGPT 20 Times a Day
OpenAI has partnered with the drug maker to embed AI throughout the business. And Stéphane Bancel says his staff should be ...
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trading higher Wednesday after the company announced an ongoing collaboration with ...
Moderna, Inc. (MRNA)
CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine ...
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Generative AI will help advance Moderna’s broad and diverse portfolio to maximize the Company’s impact on patients ...
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including ...
Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may ...
Viatris taps former Moderna executive Corinne Le Goff as new chief commercial officer
Viatris on Monday named Corinne Le Goff as the Canonsburg pharmaceutical company’s chief commercial officer. Le Goff takes ...
Top Moderna Shareholders
Moderna Inc. (MRNA) is a pharmaceutical and biotechnology company that develops medicines based on messenger ribonucleic acid (mRNA), which transfers genetic information to the cellular machinery ...
Moderna partners with OpenAI to supercharge mRNA research with genAI
Moderna announced a partnership with OpenAI, the company behind ChatGPT, to further incorporate AI across its mRNA drug ...
Loading the latest forecasts...